XOMA Royalty Corporation Releases 2025 Annual Report – Critical Takeaways for Investors

XOMA Royalty Corporation (Nasdaq: XOMA, XOMAP, XOMAO) has filed its annual report (Form 10-K) for the fiscal year ending December 31, 2025. The report provides an important update on the company’s financial condition, capital structure, and significant events that could be pivotal for shareholders and potential investors. Below, we break down the key information and potential market-moving items disclosed in the filing.

Key Points from the 2025 10-K Filing

• Fiscal Year End: December 31, 2025
• Exchange Listings:
  • Common Stock (XOMA) – Nasdaq Global Market
  • 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) – Nasdaq Global Market
  • Depositary Shares (each representing 1/1000th interest in 8.375% Series B Cumulative Perpetual Preferred Stock, XOMAO) – Nasdaq Global Market
• Commission File Number: 001-39801
• Corporate Contact: (510) 204-7200
• Not a Well-Known Seasoned Issuer: XOMA is not classified as a well-known seasoned issuer under SEC rules, signaling its size and market profile.

Capital Structure and Equity Information

• Common and Preferred Stock:
  • 5003 shares of temporary equity outstanding as of December 31, 2025
  • 984,000 shares of Series A Preferred Stock outstanding at 2024 and 2025 year-end
  • Depositary shares in respect to Series B Preferred Stock are traded, with each representing a 1/1000th interest in a share
• Dividend Declarations: The company maintains several classes of preferred shares, each with associated dividends, which may be relevant for yield-focused investors.
• Share Repurchase Program: The filing references an ongoing stock repurchase program initiated in January 2024, which could influence share supply and potentially support the share price during execution.

Warrants, Stock Awards, and Potential Dilution

• Outstanding Warrants: XOMA has multiple classes of outstanding warrants with exercise prices ranging from \$14.71 to \$50.00 per share. These instruments could potentially dilute existing shareholders if exercised, especially if the share price appreciably exceeds the strike prices.
• Antidilutive Securities: Certain warrants, performance shares, and preferred shares were excluded from EPS calculations as they were antidilutive in 2024 and 2025—meaning their exercise would reduce reported earnings per share, a factor for valuation models.
• Performance Stock Units (PSUs): The company has adopted significant performance-based equity awards, with vesting tied to stock price hurdles at \$30, \$35, \$40, and \$45 per share. This aligns management incentives with shareholder value creation and could lead to substantial dilution if the stock price appreciates strongly.

Debt and Liquidity

• Debt Instruments: The company maintains a Blue Owl Commercial Payment Backed Loan Agreement, including delayed draw term loans and associated warrants. The structure and covenants of this facility can impact liquidity, interest expense, and flexibility.
• Cash and Cash Equivalents: XOMA reports holdings in US Treasury Bills and money market funds, with fair value measurement in Level 1 inputs, suggesting liquidity and transparency in valuation.

Tax, Segment, and Geographical Reporting

• Open Tax Years: Federal open tax years include 2021–2025, and state/local for 2021–2025, which could have implications for potential tax liabilities or settlements.
• Business Segments: XOMA reports as a single reportable segment, focused on royalty acquisition and management.
• Geographical Exposure: The company reports exposure across the US and Asia-Pacific, indicating a degree of international diversification.

Potential Price-Sensitive and Shareholder-Relevant Items

• Stock Repurchase Program: The continuation of the buyback program may signal confidence from management and could provide downside support for the share price.
• Performance-Based Incentives: The large tranches of PSUs tied to aggressive stock price hurdles could drive management to pursue value-creating transactions or operational improvements. If these hurdles are met, significant dilution could occur, which is both an opportunity and a risk for existing shareholders.
• Warrants: The potential for warrant exercises at high strike prices may act as a cap on near-term share price appreciation but could also provide an influx of cash if exercised.
• Preferred Dividends: The company’s obligation to pay dividends on its preferred shares creates a fixed charge that may impact free cash flow available to common shareholders.

Other Noteworthy Points

• Not a Well-Known Seasoned Issuer: XOMA’s status may limit its ability to raise capital rapidly in public markets compared to larger peers.
• No Securities Registered under Section 12(g): There are no other publicly-traded securities beyond those listed on Nasdaq, reducing the risk of unexpected dilution from off-exchange instruments.

Conclusion

Investors should closely monitor the execution of the stock repurchase program, the vesting and issuance of performance stock units, and the impact of outstanding warrants on potential dilution. The combination of preferred share obligations, debt facilities, and equity-linked compensation structures makes XOMA a complex but potentially rewarding investment for those seeking exposure to royalty streams and specialty finance in life sciences.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full 10-K filing and consult with a qualified financial advisor before making investment decisions. All information is derived from XOMA Royalty Corporation’s 2025 10-K filing and public disclosures. Past performance is not indicative of future results.

View XOMA Royalty Corp Historical chart here